Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis

Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia

NCT01284010 ·Status: COMPLETED

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

NCT01649791 ·Status: TERMINATED ·Phase: NA

Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older

NCT00535873 ·Status: COMPLETED ·Phase: PHASE2

Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

NCT00103558 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

NCT02582879 ·Status: COMPLETED

Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia

NCT01138306 ·Status: COMPLETED

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

NCT05641831 ·Status: RECRUITING ·Phase: PHASE2

Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia

NCT01057290 ·Status: COMPLETED

Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)

NCT00759798 ·Status: COMPLETED ·Phase: PHASE2

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

NCT06978088 ·Status: RECRUITING ·Phase: PHASE2

Prospective Collection of Biological Data of Prognostic Relevance in Patients With B-Cell Chronic Lymphocytic Leukemia

NCT00917540 ·Status: UNKNOWN

A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

NCT01035216 ·Status: TERMINATED ·Phase: PHASE1

Lenalidomide and Obinutuzumab for Previously Untreated CLL

NCT02371590 ·Status: WITHDRAWN ·Phase: PHASE2

A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)

NCT01580228 ·Status: COMPLETED ·Phase: PHASE3

S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy

NCT01360125 ·Status: COMPLETED

Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL

NCT00344786 ·Status: TERMINATED ·Phase: PHASE1

Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia

NCT01150058 ·Status: COMPLETED

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

NCT01271283 ·Status: WITHDRAWN ·Phase: PHASE2

Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia

NCT01380587 ·Status: COMPLETED

Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

NCT02200848 ·Status: TERMINATED ·Phase: PHASE1

Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia (CLL) Using Deuterated Water

NCT01110850 ·Status: COMPLETED

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01351896 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00482352 ·Status: COMPLETED

Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

NCT00751296 ·Status: TERMINATED ·Phase: PHASE2

Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia

NCT01421875 ·Status: COMPLETED